Impel NeuroPharma’s $80 Million Initial Public Offering

Fenwick & West LLP advised Impel NeuroPharma on the deal.

Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, announced its initial public offering of 5,333,334 shares of common stock at a price of $15 per share, for total proceeds of $80 million.

The shares began trading on the Nasdaq Global Market under the ticker symbol IMPL. In addition, Impel granted the underwriters a 30-day option to purchase up to an additional 800,000 shares of common stock.

Cowen and Guggenheim Securities acted as joint bookrunning managers for the proposed offering. Wedbush PacGrow acted as lead manager.

The Fenwick transaction team included corporate partners Alan Smith (Picture) and Amanda Rose and associates Ryan Mitteness, Steven Jean, Adam Conway, law clerk Angelo Angelino and senior paralegal Ellen Welichko; executive compensation and employee benefits partner Nancy Chen, counsel Nicholas Frey and associate Jonathan Stephenson; and intellectual property partners Daniel Becker and Antonia Sequeira and counsel Charles Cathey.

Involved fees earner: Daniel Becker – Fenwick & West LLP; Charles Cathey – Fenwick & West LLP; Nancy Chen – Fenwick & West LLP; Adam Conway – Fenwick & West LLP; Nicholas Frey – Fenwick & West LLP; Steven Jean – Fenwick & West LLP; Ryan Mitteness – Fenwick & West LLP; Amanda Rose – Fenwick & West LLP; Antonia Sequeira – Fenwick & West LLP; Alan Smith – Fenwick & West LLP; Jonathan Stephenson – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Impel NeuroPharma Inc.;

Author: Martina Bellini